TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2823594
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psyllium gum and wheat bran
Study: 2823594
Drug: Control (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (4 g/d fiber)
Study: 29859267
Drug: TeleCAM (home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: TeleCAM (home-based telerehabilitation intervention using pre-loaded tablets and IVR system technology)
Study: 27662565
Drug: Daily sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sedation interruption + protocolized sedation
Study: 27662565
Drug: Daily sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sedation interruption + protocolized sedation (for children > 4 years old)
Study: 22288788
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy group (n = 14)
Study: 17697398
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g short-chain fructo-oligosaccharides (sc-FOS) per day for 6 weeks
Study: 17697398
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g placebo (sucrose and maltodextrins) per day for 6 weeks
Study: 10635157
Drug: Mini-transitional implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-transitional implants (MTIs) placed medially to the permanent implants.
Study: 8544287
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of fentanyl and midazolam with 67 % N2O
Study: 8544287
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of fentanyl and midazolam without N2O
Study: 22664648
Drug: Medtable™ EMR-integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medtable™ EMR-integrated tool for medication management
Study: 14583064
Drug: Sibutramine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10-20 mg daily)
Study: 1284156
Drug: Gallopamil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (50 mg t.i.d. for 4 weeks)
Study: 6377491
Drug: Orgotein 16
Normalized name: Orgotein
DrugBank: Orgotein (DB11444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgotein 16 mg
Study: 6377491
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate 40 mg
Study: 6377491
Drug: Orgotein 8
Normalized name: Orgotein
DrugBank: Orgotein (DB11444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgotein 8 mg
Study: 26695494
Drug: Nonpsychotropic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpsychotropic medications
Study: 21308265
Drug: Standard anxiolytics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anxiolytics (benzodiazepines, buspirone, antidepressants)
Study: 12378657
Drug: Crystalloid intravenous
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid intravenous fluid
Study: 12378657
Drug: Colloid intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid intravenous fluid
Study: 9988284
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors for left ventricular dysfunction (LVD) and/or diabetes mellitus (DM)
Study: 9988284
Drug: Aspirin for
Normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin for history of myocardial infarction (MI)
Study: 9988284
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for chronic atrial fibrillation (AF)
Study: 9988284
Drug: Any or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any or all indicated medications
Study: 1967677
Drug: Intramuscular hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular hydrocortisone (200 mg)
Study: 1967677
Drug: Rectal hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal hydrocortisone (200 mg)
Study: 7375869
Drug: Biarison (600-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biarison (600-900 mg daily)
Study: 7375869
Drug: Indomethacin (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50-100 mg daily)
Study: 7375869
Drug: Biarison (used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biarison (used in treatment of active SLE)
Study: 30461337
Drug: Dienogest 2
Normalized name: dienogest 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 2 mg once daily
Study: 20204674
Drug: Raltitrexed (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed (3 mg/m² i.v. every 21 days) plus gefitinib (250 mg p.o. daily)
Study: 20204674
Drug: Raltitrexed (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed (3 mg/m² i.v. every 21 days)
Study: 18809275
Drug: L-carnitine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (0.5 g/day for two days, followed by 1g/day for two days, and then 2g/day for 10 days)
Study: 18809275
Drug: L-carnitine (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (during exploratory analysis)
Study: 10848879
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (6 U/m2/day) with low dose ethinyl oestradiol, administered either once daily (OD) or twice daily (BID)
Study: 10848879
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (6 U/m2/day) with low dose ethinyl oestradiol
Study: 29460811
Drug: Viscosity-regulating pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscosity-regulating pectin solution (VREF group, n = 15)
Study: 29460811
Drug: Conventional enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional enteral nutrition administration (Control group, n = 12)
Study: 26764413
Drug: ivabradine 2×7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 2×7.5 mg
Study: 25018120
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) 0.5 mL intramuscularly (containing 40, 8, and 32 D antigen units for serotypes 1, 2, and 3)
Study: 19446951
Drug: Cizolirtine citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cizolirtine citrate 800 mg/d
Study: 19446951
Drug: Oxybutynin 15
Normalized name: oxyBUTYnin 15 mg/24 hr oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 15 mg/d
Study: 15640476
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg Zn daily)
Study: 12195349
Drug: Saquinavir in
Normalized name: Product containing saquinavir in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir in combination with either ritonavir or nelfinavir, plus delavirdine, adefovir, or both; duration: 48 weeks
Study: 11551136
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment after neoadjuvant chemotherapy
Study: 9923574
Drug: Tacrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine treatment with serum concentrations above 7 ng/ml
Study: 9923574
Drug: Tacrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine treatment with serum concentrations below 7 ng/ml
Study: 9923574
Drug: Tacrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine treatment with serum concentrations above 5 ng/ml
Study: 9923574
Drug: Tacrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine treatment with serum concentrations above 9 ng/ml
Study: 7014073
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg morphine
Study: 3073322
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg new analgesic
Study: 3073322
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg new analgesic
Study: 22595934
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost ophthalmic solution
Study: 16216827
Drug: ghrelin 40
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ghrelin 40 mug administered intravenously over 30 minutes
Study: 16216827
Drug: saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline administered intravenously over 30 minutes
Study: 12665160
Drug: Grippostad-C (acetaminophen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grippostad-C (acetaminophen, caffeine, chlorpheniramine, ascorbic acid)
Study: 12665160
Drug: Acetaminophen, caffeine,
Normalized name: Acetaminophen, Caffeine, and Dihydrocodeine Bitartrate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, caffeine, ascorbic acid (reference 2)
Study: 9461937
Drug: Tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 40 mg rectally followed by 20 mg daily for 7 days
Study: 9461937
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg rectally followed by 20 mg daily for 7 days
Study: 27101675
Drug: CPAP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP combined with modified oral appliance (MOA)
Study: 23746205
Drug: Dried purple
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried purple carrot (118.5 mg/day of anthocyanins and 259.2 mg/day of phenolic acids for 4 weeks)
Study: 16737761
Drug: Glutamate infusion
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate infusion during 1h immediately after skin closure
Study: 16737761
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during 1h immediately after skin closure
Study: 3317180
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg of epsilon‐aminocaproic acid (EACA), orally every 4 hours for 5 days (maximum 30 g/day)
Study: 29579763
Drug: Individualised homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised homeopathic medicine
Study: 16020212
Drug: ALA-IPL treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-IPL treatment
Study: 10540045
Drug: OBTM (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBTM (Omeprazole 20 mg b.d., Bismuth 120 mg q.d.s., Tetracycline 500 mg q.d.s., Metronidazole 250 mg q.d.s.)
Study: 10540045
Drug: RbcTM (Ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RbcTM (Ranitidine bismuth citrate 400 mg b.d., Tetracycline 500 mg q.d.s., Metronidazole 250 mg q.d.s.)
Study: 8905425
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide (100 micrograms three times daily for 10 days)
Study: 8905425
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no octreotide treatment)
Study: 9391254
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide
Study: 1804603
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Aspirin (50 mg/day)
Study: 6136132
Drug: H1 +
Normalized name: Histamine H1 Receptor Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 + H2-antagonists (Chlorpheniramine 4 X 4 mg/d and Cimetidine 4 X 400 mg/d for 4 weeks)
Study: 6136132
Drug: H1-antagonist alone
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1-antagonist alone (Chlorpheniramine 4 X 4 mg/d for 4 weeks)
Study: 6136132
Drug: H1 +
Normalized name: Histamine H1 Receptor Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 + H2-antagonists (Chlorpheniramine and Cimetidine for 4 weeks)
Study: 6136132
Drug: H1-antagonist (Chlorpheniramine)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1-antagonist (Chlorpheniramine)
Study: 6136132
Drug: H1 +
Normalized name: Histamine H1 Receptor Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 + H2-antagonists
Study: 26072396
Drug: Pretreatment screening
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment screening for TPMT variants with dose reduction (50% for heterozygous carriers, 0%-10% for homozygous carriers)
Study: 10861154
Drug: Posterior lumbar
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior lumbar plexus block with 0.4 ml/kg bupivacaine, 0.5%, with epinephrine
Study: 8477964
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (13 to 15 mg/kg/day)
Study: 31931848
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin 10 mg/kg once daily for 3 days
Study: 30148871
Drug: Time-averaged albuminuria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-averaged albuminuria cut-off of 900 mg/day
Study: 24131075
Drug: CP 3
Normalized name: Pseudoephed/Acetaminop/Dpha/Cp 30 mg-500 mg-25 mg-2 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP 3 g (Group B)
Study: 24131075
Drug: CP 3
Normalized name: Pseudoephed/Acetaminop/Dpha/Cp 30 mg-500 mg-25 mg-2 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP 3 g and vitamin C 500 mg (Group C)
Study: 24131075
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (Group A)
Study: 24131075
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg (Group D)
Study: 18407003
Drug: Web-based smoking-cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Web-based smoking-cessation program plus nicotine patch
Study: 12428224
Drug: Oral pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pulse prednisolone, methotrexate, plus sulfasalazine
Study: 1924640
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alprazolam four times daily
Study: 1924640
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg fluoxetine every morning
Study: 1924640
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alprazolam four times daily and 60 mg fluoxetine every morning
Study: 7043341
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel (2 ml containing 0.5 mg PGE2)
Study: 7043341
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (gel without PGE2)
Study: 7043341
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel (0.5 mg) in subsequent open study
Study: 29229898
Drug: Hepabulin (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepabulin (10,000 units) intravenously injected intraoperatively, daily for 1 week, weekly for 1 month, and then once per month
Study: 25440110
Drug: Infusions prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions prepared from 2 g of C citratus leaf powder once daily for 30 days
Study: 25440110
Drug: Infusions prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions prepared from 4 g of C citratus leaf powder once daily for 30 days
Study: 25440110
Drug: Infusions prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions prepared from 8 g of C citratus leaf powder once daily for 30 days
Study: 21060071
Drug: Omega-3-acid ethyl
Normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3-acid ethyl esters-90 (1 g/d for 1 year)
Study: 7512433
Drug: Methylprednisolone 125
Normalized name: methylprednisolone 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 125 mg
Study: 16416000
Drug: Bicyclo tablets
Normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicyclo tablets
Study: 12549799
Drug: Bifidobacteria Bb12
Normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacteria Bb12 supplement
Study: 12549799
Drug: Bifidobacteria Bb12
Normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacteria Bb12 and Streptococcus thermophilus supplement
Study: 12549799
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula without supplement (Control)
Study: 9625220
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg caffeine
Study: 2658673
Drug: Intravenous analgosedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgosedation with midazolam (0.1 mg/kg) and fentanyl (2 micrograms/kg)
Study: 21939716
Drug: Vi polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi polysaccharide vaccine
Study: 26352252
Drug: 30-gauge needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-gauge needle for facial injections
Study: 21483004
Drug: docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel plus high-dose calcitriol (DN-101)
Study: 17723081
Drug: Dose-separated ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-separated ferrous sulfate with MMF (days 9 to 16)
Study: 17723081
Drug: Polysaccharide iron
Normalized name: Polysaccharide Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide iron complex administered 2 hours after MMF (days 9 to 16)
Study: 10589629
Drug: 3.75 mg/mL
Normalized name: threonine 3.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg/mL ropivacaine
Study: 10589629
Drug: 7.5 mg/mL
Normalized name: pectin 7.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/mL ropivacaine
Study: 8933852
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of alfentanil (0.75 mg bolus followed by 0.36 mg/h for 24 h)
Study: 8933852
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of alfentanil (0.36 mg/h for 24 h)
Study: 1680361
Drug: Fentanyl 7
Normalized name: FENTANYL 75MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 7 micrograms kg‐1 followed by infusion of 3 micrograms kg‐1 h‐1
Study: 24218528
Drug: Rivastigmine (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (transdermal patch of 9.5 mg/day)
Study: 20538557
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sibutramine once daily for 19 months
Study: 20538557
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg sibutramine once daily for 19 months
Study: 16291416
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BIAsp 30 monotherapy
Study: 10498359
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and subcutaneous epinephrine with bovine topical thrombin (1000 U/ml)
Study: 10498359
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no epinephrine, only bovine topical thrombin)
Study: 28266591
Drug: Aggressive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive hydration (20 ml/kg bolus followed by 3 ml/kg/h)
Study: 28266591
Drug: Standard hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hydration (10 ml/kg bolus followed by 1.5 ml/kg/h)
Study: 25864739
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) at 0.067 mg/kg/day
Study: 24007461
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (from <5 mg/L to ≥5 mg/L, n = 45)
Study: 24007461
Drug: Group 4
Normalized name: Chlamydophila psittaci biogroup 4 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4 (from ≥5 mg/L to ≥5 mg/L, n = 80)
Study: 12875938
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel (10 cc of 2% lidocaine gel)
Study: 12875938
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve block (10 cc of 1% lidocaine solution injected under ultrasound guidance)
Study: 9344323
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with DOX/DDP
Study: 9344323
Drug: Histological response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Histological response to neoadjuvant chemotherapy
Study: 9344323
Drug: Change of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change of chemotherapy for poor histological response
Study: 9344323
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose intensity with G-CSF
Study: 9344323
Drug: Incorporation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorporation of new agents like Ifosfamide
Study: 9344323
Drug: Various drug
Normalized name: VARIOUS DRUG CLASSES IN ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drug administration methods
Study: 1314711
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of trivalent oral poliovirus vaccine (TOPV) at birth and subsequent doses at 2, 4, and 9 months of age (Group A)